Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 425Neoplasms 284Carcinoma, Non-Small-Cell Lung 274Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 171Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 100Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 78Small Cell Lung Carcinoma 72Head and Neck Neoplasms 70Brain Neoplasms 70Glioblastoma 65Esophageal Neoplasms 65Endometrial Neoplasms 59Colonic Neoplasms 59Melanoma 56Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Glioma 48

Interventions

irinotecan sucrosofate 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Efficacy and Safety × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡